NCT03300947View on ClinicalTrials.gov

Psilocybin for Treatment of Obsessive Compulsive Disorder

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 2, 2019

Primary Completion Date

October 30, 2023

Study Completion Date

December 30, 2023

Conditions
Obsessive-compulsive Disorder (OCD)
Interventions
DRUG

Psilocybin 100 mcg/kg

"Psilocybin belongs to the class of hallucinogen or psychedelic drugs. It is one of the major psychoactive components in mushrooms of the Psilocybe genus (magic mushrooms)."

DRUG

Psilocybin 300 mcg/kg

"Psilocybin belongs to the class of hallucinogen or psychedelic drugs. It is one of the major psychoactive components in mushrooms of the Psilocybe genus (magic mushrooms)."

DRUG

Lorazepam 1 mg

A medication used to treat anxiety belonging to a class of drugs known as benzodiazepines, which act on the central nervous system to produce a calming effect. This drug works by enhancing the effects of a certain natural chemical in the body (GABA).

Trial Locations (1)

85724

University of Arizona, Tucson

All Listed Sponsors
lead

University of Arizona

OTHER

NCT03300947 - Psilocybin for Treatment of Obsessive Compulsive Disorder | Biotech Hunter | Biotech Hunter